Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill
November 06, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
– Top-Line Results Expected by the Fourth Quarter of 2018 – – NDA Submission for LDL-C Lowering Indication for the Bempedoic Acid / Ezetimibe Combination Pill Expected by First Quarter 2019 – ANN...